We’ve talked so much recently about the Woodruff Health Sciences Center’s clinical response to COVID-19—and rightfully so. Our health care teams have risen to an almost unimaginable challenge in recent months, and they’ve done so with their customary compassion and excellence.
What you may not know is that another component of our tripartite mission—our research enterprise—has responded to the crisis with equal distinction. In spite of the challenges posed by the pandemic, Emory’s research team has emerged as a national leader in COVID-related research, currently ranking number three nationwide in COVID NIH awards among universities, and number five in the country when non-university research institutes are included.
Our COVID-19 activities span from advancing understanding of the virus to developing quicker and more accurate tests to finding treatments and a vaccine, and the numbers are impressive. As of September 6, the Woodruff Health Sciences Center has had 315 submissions from 186 primary investigators for a total of $177.1 million in proposals. This has already yielded 81 sponsored awards from 58 PI’s for a total of $89 million. In addition, we have successfully published 352 Emory-authored COVID-related manuscripts to date.
Driven in part by our successful COVID-19 research efforts, WHSC has achieved a remarkable year of research funding overall with $782 million in awards – an extraordinary increase of $140 million over FY19!
Thanks to everyone across all aspects of our research enterprise for continuing to excel under challenging circumstances and for leading the nation’s efforts to advance our understanding, prevention, and treatment of COVID-19.
Please direct questions and comments to evphafeedback@emory.edu.
Jonathan S. Lewin, MD, FACR Executive Vice President for Health Affairs, Emory University Executive Director, Woodruff Health Sciences Center CEO and Chairman of the Board, Emory Healthcare |